Radium-223 dichloride (Xofigo, BAY88-8223)
17096
Phase 2 small_molecule completed
Quick answer
Radium-223 dichloride (Xofigo, BAY88-8223) for Breast Neoplasms is a Phase 2 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Breast Neoplasms
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed